Cited by 497Epigenetics and DNA MethylationGenomics and Chromatin DynamicsChromatin Remodeling and Cancer

The DOI matches its Crossref record; 215 of the 290 references it cites were found in a registry or an index, and 72 are not checked yet; none of the 223 sources its claims cite is checked for support yet.

Epigenetics and cancer

Open access
Lund, Anders H., van Lohuizen, Maarten·2004·Genes & Development

Abstract

Epigenetic mechanisms act to change the accessibility of chromatin to transcriptional regulation locally and globally via modifications of the DNA and by modification or rearrangement of nucleosomes. Epigenetic gene regulation collaborates with genetic alterations in cancer development. This is evident from every aspect of tumor biology including cell growth and differentiation, cell cycle control, DNA repair, angiogenesis, migration, and evasion of host immunosurveillance. In contrast to genetic cancer causes, the possibility of reversing epigenetic codes may provide new targets for therapeutic intervention.

Checked 2026-10-06 · 72 references not checked yet

Overview

Integrity signals

Registry

Crossref · 10.1101/gad.1232504

Cites

215 of 287 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 of 223 cited sources checked · 0 supported · 0 flagged

Show all 112 claims

  • It may state two separate claims as one. 70
  • Probably not a substantial claim. 19
83 of 83
  • The paper relies on this without support.

    Epigenetic changes that contribute to cancer can be reversed pharmacologically to produce therapeutic benefit.

    “In contrast to genetic cancer causes, the possibility of reversing epigenetic codes may provide new targets for therapeutic intervention.”
  • The paper relies on this without support.

    Understanding the molecular details of epigenetic cancer mechanisms will translate into new drug development strategies.

    “Understanding the molecular details behind”
  • The paper relies on this without support.

    Findings from model organisms and cell lines are informative about human cancer epigenetics.

    “Mouse models have further validated a role for genomic hypomethylation in tumor formation”
  • The paper relies on this without support.

    Epigenetic alterations observed in cancer cell lines and xenografts reflect primary human tumor biology.

    “MBD2 knockdown in human cancer cell lines was found to suppress tumorigenesis in a mouse xenograft model”
  • The authors state this as an assumption.

    Reversal of epigenetic silencing will reinstate cellular cancer defense mechanisms.

    “The fundamental principle behind this type of epigenetic therapy is that reversal of epigenetic silencing will reinstate cellular cancer defense mechanisms”
  • The paper relies on this without support.

    There is limited knowledge about possible adverse effects in patients.

    “relatively little is known about potential side effects in patients”
  • The paper relies on this without support.

    Not all epigenetic marks are known.

    “not all epigenetic marks are known”
  • The paper relies on this without support.

    Only few of the known epigenetic marks are understood in any detail.

    “only few of the known ones are understood in any detail”
8 of 8

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

2 retracted

Flagged first, then by citations

Show all 290 references

3 of the 290 references couldn’t be matched to a known paper.

Research works printed but not linked: 26

  1. 2001, Cancer Res., 61, 2409
  2. 1999, Cancer Res., 59, 74
  3. 1999, Cancer Res., 59, 3855
  4. 2002, Cancer Res., 62, 4736
  5. 2001, Cancer Res., 61, 8094
  6. 2000, Cancer Res., 60, 2368
  7. 2001, Cancer Res., 61, 3225
  8. 2003, Clin. Cancer Res., 9, 4415
  9. 1995, Cancer Res., 55, 5195
  10. 1998, Cancer Res., 58, 4238
  11. 1995, Cancer Res., 55, 4525
  12. 1997, Cancer Res., 57, 808
  13. 2003, Cancer Res., 63, 7619
  14. 2000, Cancer Res., 60, 3359
  15. 1996, Oncogene, 12, 1565
  16. 1998, Cancer Res., 58, 591
  17. 2002, Curr. Issues Mol. Biol., 4, 111
  18. 1993, Oncogene, 8, 1063
  19. 2003, Int. J. Oncol., 23, 1663
  20. 2003, Cancer Res., 63, 1114
  21. 2003, Cancer Res., 63, 560
  22. 2003, Cancer Res., 63, 3511
  23. 1999, Cancer Res., 59, 5438
  24. 2002, Cancer Res., 62, 2378
  25. 1999, Nat. Genet., 23, 62
  26. 2000, Cancer Res., 60, 6171

Cited by

Sorted by citations

Metadata

Authors
Lund, A. H., & van Lohuizen, M.
Affiliations
The Netherlands Cancer Institute (NL)
Venue
Genes & Development
Published
2004-10-01
Volume
18
Issue
19
Pages
2315-2335
ISSN
  • 0890-9369 (ISSN-L)
  • 1549-5477
OpenAlex
W2136492640
Cited by
489
References
290
Citations by year
2026: 5 · 2025: 3 · 2024: 5 · 2023: 9 · 2022: 9 · 2021: 15 · 2020: 11 · 2019: 13 · 2018: 11 · 2017: 19 · 2016: 23 · 2015: 22 · 2014: 25 · 2013: 34 · 2012: 23
Type
posted content
Language
en
Open access
Locations
  • Genes & Development (publishedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
epigenetics, cancer, chromatin accessibility, DNA methylation, histone modifications, transcriptional regulation, tumor biology, cell cycle regulation, DNA repair, angiogenesis, cell migration, immune evasion, epigenetic therapy
MeSH terms
Cell Cycle, Cell Differentiation, Cell Division, DNA Repair, Gene Expression Regulation, Humans, Neoplasms, Neovascularization, Pathologic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review